Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Fineline Cube May 12, 2026
Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Fineline Cube May 12, 2026
Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Fineline Cube May 12, 2026
Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Fineline Cube May 12, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Fineline Cube May 13, 2026
Company Drug

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Fineline Cube May 13, 2026
Company Drug

Yifan Pharmaceutical’s F-652 Wins NMPA IND for GVHD Therapy

Fineline Cube Jan 6, 2026

Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that its Recombinant Human Interleukin‑22‑Fc Fusion Protein for...

Policy / Regulatory

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs

Fineline Cube Jan 6, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...

Company Deals

Mabwell’s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson’s Trials

Fineline Cube Jan 6, 2026

Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non‑exclusive clinical...

Company Deals

Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases

Fineline Cube Jan 6, 2026

Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY)...

Company Drug

Ark Biopharma’s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years

Fineline Cube Jan 6, 2026

Shanghai Ark Biopharmaceutical Co., Ltd. announced that Azstarys (serdexmethylphenidate, dexmethylphenidate) has been approved by China’s...

Company Drug

Hengrui’s HRS9531 and AR‑PROTAC Win NMPA IND Approval for Clinical Trials

Fineline Cube Jan 6, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that four drug candidates—HRS9531 (GLP‑1R/GIPR...

Company Drug

Genhouse Bio’s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals

Fineline Cube Jan 6, 2026

Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China’s...

Company Deals

Touchstone Medical Partners with INSPUR to Advance Healthcare AI and Medical Robots

Fineline Cube Jan 6, 2026

Touchstone International Medical Science Co., Ltd. (SHA: 688013) announced a strategic partnership with INSPUR Co.,...

Company Deals Drug

Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets

Fineline Cube Jan 6, 2026

Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with...

Company Drug

Humanwell Healthcare’s HW221043 Receives NMPA Approval for Advanced Solid Tumor Trials

Fineline Cube Jan 6, 2026

Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its independently developed HW221043 tablets have...

Company Deals

Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform

Fineline Cube Jan 6, 2026

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement...

Company Drug

Frontier Biotech’s FB7013 Wins NMPA IND for MASP‑2 siRNA in IgA Nephropathy

Fineline Cube Jan 5, 2026

Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND)...

Company Deals R&D

Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal

Fineline Cube Jan 5, 2026

Insilico Medicine (HKG: 3696) announced a multi‑year R&D collaboration with Servier to identify and develop...

Company Drug

Kelun-Biotech’s sac-TMT Wins Breakthrough Therapy Designation for First‑Line NSCLC

Fineline Cube Jan 5, 2026

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac‑TMT, SKB264/MK‑2870), its TROP2‑directed...

Company Deals

Kangtai Biological Co‑founds Beijing Laboratory to Advance Synthetic Immunology and Vaccine Manufacturing

Fineline Cube Jan 5, 2026

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that its wholly‑owned subsidiary Minhai Biotechnology...

Company Drug

Kelun-Biotech’s ITGB6 ADC SKB105 Wins NMPA IND Approval

Fineline Cube Jan 5, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Investigational New Drug (IND) application...

Company Deals

Huadong Medicine Licenses MC2’s PAD‑Based Biomee Skincare for Greater China

Fineline Cube Jan 5, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly‑owned...

Policy / Regulatory

CMS Unveils BALANCE Model to Expand GLP-1 Access for Medicare/Medicaid

Fineline Cube Jan 5, 2026

The U.S. Centers for Medicare & Medicaid Services (CMS) unveiled the BALANCE Model (Better Approaches...

Company Drug

GenEditBio’s GEB-101 Wins FDA IND Approval as World’s First Corneal Gene Therapy

Fineline Cube Jan 5, 2026

GenEditBio announced that GEB-101, its self‑developed in vivo genome editing investigational drug, has received Investigational...

Company Drug

Merck’s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension

Fineline Cube Jan 5, 2026

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world’s...

Posts pagination

1 … 60 61 62 … 664

Recent updates

  • Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal
  • Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection
  • Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer
  • Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China
  • Sichuan Biokin’s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Company Medical Device

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Company Drug

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.